Cabaletta Bio Inc (CABA)

$8.24

+0.04

(+0.49%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Cabaletta Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 112.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 222.4%

Performance

  • $7.93
    $8.76
    $8.24
    downward going graph

    3.76%

    Downside

    Day's Volatility :9.47%

    Upside

    5.94%

    downward going graph
  • $6.90
    $26.35
    $8.24
    downward going graph

    16.26%

    Downside

    52 Weeks Volatility :73.81%

    Upside

    68.73%

    downward going graph

Returns

PeriodCabaletta Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-51.85%
6.1%
0.0%
6 Months
-61.32%
4.9%
0.0%
1 Year
-31.72%
13.6%
0.0%
3 Years
0.37%
14.3%
-22.5%

Highlights

Market Capitalization
380.9M
Book Value
$4.6
Earnings Per Share (EPS)
-1.71
Wall Street Target Price
33.56
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.16%
Return On Equity TTM
-49.06%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-84.3M
Diluted Eps TTM
-1.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.13
EPS Estimate Next Year
-2.22
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Cabaletta Bio Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 307.28%

Current $8.24
Target $33.56

Technicals Summary

Sell

Neutral

Buy

Cabaletta Bio Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cabaletta Bio Inc
Cabaletta Bio Inc
-32.57%
-61.32%
-31.72%
0.37%
-18.0%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cabaletta Bio Inc
Cabaletta Bio Inc
NA
NA
NA
-2.13
-0.49
-0.31
NA
4.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cabaletta Bio Inc
Cabaletta Bio Inc
Buy
$380.9M
-18.0%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • BlackRock Inc

    8.40%
  • State Street Corporation

    7.75%
  • Jennison Associates LLC

    7.09%
  • Fred Alger Management, LLC

    6.44%
  • Adage Capital Partners Gp LLC

    6.29%
  • T. Rowe Price Investment Management,Inc.

    5.12%

Company Information

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un

Organization
Cabaletta Bio Inc
Employees
118
CEO
Dr. Steven A. Nichtberger M.D.
Industry
Health Technology

FAQs